Neumora Therapeutics Holds Annual Stockholders Meeting

Neumora Therapeutics, Inc. ( (NMRA) ) has provided an announcement.

On May 28, 2025, Neumora Therapeutics, Inc. held its Annual Meeting of Stockholders, where four proposals were voted on by the stockholders. The proposals included the election of two Class II directors, the ratification of Ernst & Young LLP as the independent auditor for 2025, the approval of repricing certain stock options, and amendments for a reverse stock split. These decisions are poised to influence the company’s governance and financial strategies moving forward.

The most recent analyst rating on (NMRA) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Neumora Therapeutics, Inc. stock, see the NMRA Stock Forecast page.

Spark’s Take on NMRA Stock

According to Spark, TipRanks’ AI Analyst, NMRA is a Underperform.

Neumora Therapeutics, Inc. is significantly challenged by its financial position, with ongoing losses and no revenue. Technical analysis indicates bearish momentum, and valuation is difficult in the absence of earnings. While promising pipeline advancements and a strong cash position offer some optimism, the overall outlook is hindered by recent clinical setbacks and financial instability.

To see Spark’s full report on NMRA stock, click here.

More about Neumora Therapeutics, Inc.

Neumora Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on developing precision medicines for brain diseases. The company aims to address significant unmet needs in neuroscience through innovative therapeutic solutions.

Average Trading Volume: 1,065,474

Technical Sentiment Signal: Sell

Current Market Cap: $115.7M

See more data about NMRA stock on TipRanks’ Stock Analysis page.